CERUS CORP
CERSNasdaq
$3.13
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↑ +122.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$607.7M
Enterprise Value
$527.2M
P/E
—
P/S
—
P/B
9.0
EV/EBITDA
—
PEG
—
FCF Yield
-0.2%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.6M
Free Cash Flow (TTM)
-$1.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-14.1%
ROIC
—
Debt / Equity
—
Net Cash
$80.4M
Return 1Y
+128.5%
Company profile
Cerus Corporation focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America and internationally.
- CEO
- William M. Greenman
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 290
- Headquarters
- California
- Website
- cerus.com
Management & directors
- Jayaraman Vivek KChief Operating Officer
- Green Kevin DennisChief Financial Officer
- Greenman William MarinerPresident and CEO
- Menard ChrystalChief Legal Officer
- Benjamin Richard JChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
CERS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$53.7M↑ +24.1%
Diluted EPS-$0.01↓ -75.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $114.2M | $159.5M | $188.3M | $186.8M | $201.3M | $233.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$58.3M | -$48.9M | -$34.1M | -$30.1M | -$14.2M | -$8.7M |
| Net income | -$59.9M | -$54.4M | -$42.8M | -$37.5M | -$20.9M | -$15.6M |
| Diluted EPS | -$0.37 | -$0.32 | -$0.24 | -$0.21 | -$0.11 | -$0.08 |
| Operating cash flow | -$41.8M | -$33.9M | -$25.6M | -$43.2M | $11.4M | $4.8M |
| Free cash flow | -$43.4M | -$34.8M | -$27.6M | -$47.8M | $8.5M | $1.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -51.1% | -30.7% | -18.1% | -16.1% | -7.1% | -3.7% |
| Net margin | -52.4% | -34.1% | -22.7% | -20.1% | -10.4% | -6.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $43.2M | — | — | — | $53.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.8M | -$961,000.00 | -$1.4M | -$5.9M | -$3.4M | $1.2M | -$641,000.00 | -$354,000.00 |
| Net income | -$5.8M | -$2.9M | -$2.5M | -$7.7M | -$5.7M | -$19,000.00 | -$2.2M | -$1.6M |
| Diluted EPS | -$0.03 | -$0.02 | -$0.01 | -$0.04 | -$0.03 | $0.00 | -$0.01 | -$0.01 |
| Operating cash flow | $401,000.00 | $4.1M | $4.9M | -$844,000.00 | -$2.4M | $1.9M | $6.2M | -$3.0M |
| Free cash flow | $360,000.00 | $3.3M | $4.0M | -$956,000.00 | -$2.9M | $94,000.00 | $4.9M | -$3.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -13.5% | — | — | — | -0.7% |
| Net margin | — | — | — | -17.8% | — | — | — | -3.1% |
Company news
Jul 16, 2026
Jun 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Jayaraman Vivek K· Chief Operating Officer | Award | 554,529 | $0.00 | $0.00 | filing |
| 2026-06-30 | Greenman William Mariner· President and CEO | Sale | 101,919 | $2.94 | $299,937.43 | filing |
| 2026-06-30 | Jayaraman Vivek K· Chief Operating Officer | Sale | 42,359 | $2.94 | $124,658.30 | filing |
| 2026-06-30 | Green Kevin Dennis· Chief Financial Officer | Sale | 33,676 | $2.94 | $99,105.10 | filing |
| 2026-06-30 | Menard Chrystal· Chief Legal Officer | Sale | 24,329 | $2.94 | $71,597.81 | filing |
| 2026-06-30 | Green Kevin Dennis· Chief Financial Officer | Award | 63,600 | $0.00 | $0.00 | filing |
| 2026-06-30 | Jayaraman Vivek K· Chief Operating Officer | Award | 80,000 | $0.00 | $0.00 | filing |
| 2026-06-30 | Menard Chrystal· Chief Legal Officer | Award | 55,000 | $0.00 | $0.00 | filing |
| 2026-06-30 | Greenman William Mariner· President and CEO | Award | 192,500 | $0.00 | $0.00 | filing |
| 2026-06-09 | BJERKHOLT ERIC | Sale | 20,454 | $2.60 | $53,180.40 | filing |
| 2026-06-02 | Witney Frank | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | Lucena Ann | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | BJERKHOLT ERIC | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | NACHTSHEIM JAMI K | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | Gregory Dean A. | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-06-02 | Shan Hua | Award | 60,000 | $0.00 | $0.00 | filing |
| 2026-05-29 | Jayaraman Vivek K· Chief Operating Officer | Sale | 16,667 | $3.00 | $50,001.00 | filing |
| 2026-05-01 | Jayaraman Vivek K· Chief Operating Officer | Sale | 16,667 | $3.00 | $50,001.00 | filing |
| 2026-04-01 | Green Kevin Dennis· Chief Financial Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Menard Chrystal· Chief Legal Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-03-12 | Greenman William Mariner· President and CEO | Sale | 447,757 | $1.66 | $742,022.90 | filing |
| 2026-03-12 | Jayaraman Vivek K· Chief Operating Officer | Sale | 165,200 | $1.66 | $273,769.44 | filing |
| 2026-03-12 | Green Kevin Dennis· Chief Financial Officer | Sale | 127,544 | $1.66 | $211,365.92 | filing |
| 2026-03-12 | Benjamin Richard J· Chief Medical Officer | Sale | 101,740 | $1.66 | $168,603.53 | filing |
| 2026-03-09 | Benjamin Richard J· Chief Medical Officer | Sale | 40,426 | $1.88 | $76,029.18 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.